The Immunology & Cell Biology Publication of the Year Awards have been established for outstanding studies submitted by first authors who are financial members of the Australian & New Zealand Society for Immunology Inc. in the year of the article’s publication. Articles vying for these awards can come from any of the journal categories including Original Articles, Outstanding Observations, Perspectives or Short Communications. The ASI President, together with members of the ASI Executive and the Immunology & Cell Biology Editorial Board, undertakes rigorous review to identify the most outstanding original research articles based on scientific excellence. The winner of the Chris and Bhama Parish ICB Publication of the Year Award is awarded an AU$1000 scholarship provided by Wiley and the runner‐up is awarded an AU$500 scholarship provided by Thermo Fisher Scientific.

The winning paper by Katharine Goodall et al. is an Original Article entitled ”Multiple receptors converge on H2‐Q10 to regulate NK and γδT‐cell development” and was published in March 2019.¹ In this study, Dr Goodall et al. have focused their attention on a long overlooked class 1b major histocompatibility complex molecule, H2‐Q10, originally identified in 1982. Using mice deficient in H2‐Q10, Dr Goodall discovered that this molecule serves at least two distinct purposes in the development of innate lymphocytes and innate‐like T cells. First, it contributes to the development of conventional hepatic natural killer (NK) cells by stabilizing the expression of Qa‐1b and serving as a ligand for Ly49C. Second, H2‐Q10 interacts with liver‐resident γδT cells via CD8αα, and this interaction is essential for the development of liver‐resident but not intestinal CD8αα γδT cells. This work highlights how H2‐Q10 coordinates the complex interactions that regulate and shape the development of liver‐resident lymphocyte subsets.

The Original Article by David et al., “Enhanced safety and immunogenicity of a pneumococcal surface antigen A mutant whole‐cell inactivated pneumococcal vaccine,” published in July 2019, is the winner of the Thermo Fisher Scientific Publication Award for 2019.² Dr David and colleagues developed a new vaccination strategy against Streptococcus pneumoniae with the aim to enhance vaccine‐induced protection that is serotype independent. To achieve this aim, Dr David created a mutated and attenuated strain of S. pneumoniae, which after gamma irradiation was able to promote a more diverse and cross‐protective immune response than the wild‐type strain. Importantly, this whole‐cell vaccine did not require additional adjuvant, induced T helper 17 cell responses in the lungs and provided better protection of animals challenged with a heterologous strain than the gamma‐irradiated wild‐type strain did. This exciting work significantly advances pneumococcal vaccine development by revealing a new strategy to enable serotype‐independent protection.

The award‐winning papers by Drs Goodall and David highlight the outstanding quality of the work published in Immunology & Cell Biology. My very best congratulations are extended to the awardees on their success. I also thank our sponsors Wiley and Thermo Fisher Scientific for their continued support of outstanding science and scientists and the journal. It is hoped that the outstanding quality of these awarded publications will also encourage others to consider Immunology & Cell Biology as a key journal for their cutting‐edge research.

Katharine Goodall, recipient of the 2019 Chris and Bhama Parish ICB Publication of the Year Award.

Shannon David, recipient of the 2019 Thermo Fisher Scientific Publication Award.

在免疫学，细胞生物学年度大奖的出版物已经建立了提交的第一作者是谁在文章的出版年份，澳大利亚和新西兰社会为免疫公司的财务成员出色的研究。争夺这些奖项的文章可以来自任何期刊类别，包括原创文章、杰出观察、观点或短通讯。ASI 主席，以及 ASI 执行和免疫学与细胞生物学的成员编辑委员会进行严格的审查，以根据科学卓越性确定最杰出的原创研究文章。克里斯和巴马教区 ICB 年度出版物奖的获得者将获得 Wiley 提供的 1000 澳元奖学金，亚军获得赛默飞世尔科技提供的 500 澳元奖学金。

Katharine Goodall等人的获奖论文。是一篇题为“多种受体聚集在 H2-Q10 上以调节 NK 和 γδT 细胞发育”的原创文章，发表于 2019年3 月。¹在这项研究中，Goodall 博士等人. 已将注意力集中在一种长期被忽视的 1b 类主要组织相容性复合体分子 H2-Q10，最初于 1982 年发现。古道尔博士使用缺乏 H2-Q10 的小鼠发现该分子在先天淋巴细胞的发育中至少有两个不同的目的和先天样T细胞。首先，它通过稳定 Qa-1b 的表达并作为 Ly49C 的配体，促进了传统肝脏自然杀伤 (NK) 细胞的发展。其次，H2-Q10 通过 CD8αα 与肝脏驻留的 γδT 细胞相互作用，这种相互作用对于肝脏驻留的 CD8αα γδT 细胞的发育至关重要，但不是肠道 CD8αα γδT 细胞。这项工作突出了 H2-Q10 如何协调调节和塑造肝脏驻留淋巴细胞亚群发育的复杂相互作用。

David等人的原创文章“增强的肺炎球菌表面抗原 A 突变全细胞灭活肺炎球菌疫苗的安全性和免疫原性”发表于 2019 年 7 月，是 2019 年赛默飞世尔科学出版物奖的获得者^。2 David 博士及其同事开发了一种针对肺炎链球菌的新疫苗接种策略，旨在增强不依赖血清型的疫苗诱导保护。为了实现这一目标，大卫博士创造了一种变异的、减毒的肺炎链球菌菌株，与野生型菌株相比，γ 辐射后能够促进更多样化和交叉保护的免疫反应。重要的是，这种全细胞疫苗不需要额外的佐剂，在肺部诱导 T 辅助 17 细胞反应，并为受到异源毒株攻击的动物提供比 γ 辐照野生型毒株更好的保护。这项激动人心的工作通过揭示一种实现血清型独立保护的新策略，显着推进了肺炎球菌疫苗的开发。

Goodall 博士和 David 博士的获奖论文突出了发表在Immunology & Cell Biology 上的杰出工作质量。我对获奖者的成功表示最诚挚的祝贺。我还要感谢我们的赞助商 Wiley 和 Thermo Fisher Scientific 对杰出科学和科学家以及期刊的持续支持。希望这些获奖出版物的出色质量也能鼓励其他人将免疫学与细胞生物学视为其前沿研究的关键期刊。

凯瑟琳·古道尔 (Katharine Goodall)，2019 年克里斯和巴马教区 ICB 年度出版物奖获得者。

Shannon David，2019 年赛默飞世尔科学出版奖获得者。